Could a simple sugar powder help save kidneys? new trial underway for FSGS

NCT ID NCT06664814

Recruiting now Disease control Sponsor: National Human Genome Research Institute (NHGRI) Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 14, 2026 · Updated 34 times

Summary

This phase 2 trial tests an oral drug called ManNAc in 30 adults with primary focal segmental glomerulosclerosis (FSGS), a kidney disease that causes scarring and protein loss. Participants take ManNAc powder dissolved in water twice daily for 14 weeks. The study aims to see if the drug reduces protein in the urine and is safe. It is open-label, meaning everyone knows they are getting the drug.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: N-Acetyl-D-Mannosamine (ManNAc)
What this could lead to: If successful, ManNAc could offer a new oral treatment option to reduce protein loss in urine and slow kidney decline in people with FSGS.
What could go wrong: This is a small, early-phase (Phase 2) open-label study with no placebo group, so results may not prove effectiveness. Long-term safety and benefits are still unknown.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for FOCAL SEGMENTAL GLOMERULOSCLEROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

focal segmental glomerulosclerosis kidney disorder primary focal segmental glomerulosclerosis proteinuria

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

FOCAL SEGMENTAL GLOMERULOSCLEROSIS

Contacts and locations

Locations

National Institutes of Health Clinical Center
RECRUITING

Bethesda, Maryland, 20892, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.